Fortress Biotech Inc Pref Series A (FBIOP) financial statements
Fortress Biotech Inc Pref Series A reported revenue of $61M in fiscal 2025, up 15.7% a year over 9 years.
Net income was $7M and the operating margin -114.7%, against -398.7% in 2016.
The diluted share count rose 947% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Fortress Biotech Inc Pref Series A's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16M | $17M | $23M | $35M | $45M | $63M | $71M | $60M | $55M | $61M |
| Cost of revenue | $790,000 | $4M | $6M | $11M | $15M | $32M | $31M | $23M | $21M | $21M |
| Gross profit | $16M | $14M | $17M | $24M | $30M | $31M | $40M | $37M | $34M | $40M |
| Research and development | $35M | $48M | $83M | $6M | $61M | $113M | $134M | $102M | $57M | $12M |
| Selling, general and admin | $34M | $61M | $53M | $56M | $61M | $87M | $114M | $91M | $88M | $96M |
| Operating income | -$66M | -$90M | -$120M | -$111M | -$94M | -$189M | -$204M | -$142M | -$110M | -$70M |
| Interest expense | $4M | $6M | — | $12M | $15M | $15M | $12M | $15M | $14M | $10M |
| Pre-tax income | -$71M | -$98M | -$131M | -$102M | -$103M | -$164M | -$213M | -$154M | -$121M | -$34M |
| Income tax | $0 | $2M | $0 | $0 | $500,000 | $473,000 | $449,000 | $521,000 | $312,000 | -$620,000 |
| Net income | -$55M | -$67M | -$84M | -$40M | -$47M | -$65M | -$87M | -$61M | -$46M | $7M |
| EPS (diluted) | -$20.70 | -$24.15 | -$29.10 | -$10.95 | -$9.75 | -$11.85 | -$15.97 | -$8.47 | -$2.69 | -$0.07 |
| Diluted shares | 3M | 3M | 3M | 4M | 5M | 5M | 6M | 8M | 21M | 28M |
| Gross margin | 95.2% | 78.8% | 73.8% | 69.8% | 67.2% | 49.2% | 56.7% | 61.6% | 62.1% | 65.8% |
| Operating margin | -398.7% | -520.7% | -513.3% | -317.3% | -211.7% | -298.6% | -286.7% | -238.6% | -200.2% | -114.7% |
| Net margin | -334.3% | -387.8% | -360.0% | -114.4% | -104.5% | -102.5% | -121.9% | -101.6% | -83.4% | 11.1% |
Balance sheet
Fiscal years, from Fortress Biotech Inc Pref Series A's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $88M | $131M | $83M | $137M | $233M | $306M | $178M | $81M | $57M | $79M |
| Receivables | $2M | $8M | $5M | $14M | $24M | $23M | $28M | $15M | $10M | $30M |
| Inventory | $203,000 | $171,000 | $678,000 | $857,000 | $1M | $10M | $14M | $10M | $14M | $10M |
| Total current assets | $110M | $183M | $111M | $156M | $266M | $346M | $230M | $117M | $90M | $124M |
| Property, plant and equipment | $7M | $7M | $12M | $12M | $12M | $15M | $13M | $7M | $3M | $3M |
| Goodwill | $19M | $19M | — | — | — | — | — | — | — | — |
| Total assets | $171M | $246M | $141M | $226M | $333M | $397M | $294M | $168M | $144M | $186M |
| Total current liabilities | $57M | $71M | $56M | $46M | $52M | $101M | $128M | $85M | $71M | $50M |
| Total liabilities | $88M | $125M | $121M | $154M | $136M | $171M | $244M | $166M | $146M | $123M |
| Shareholders' equity | $38M | $53M | $2M | $26M | $100M | $109M | $42M | $23M | $23M | $50M |
| Net debt | -$88M | -$95M | -$66M | -$137M | -$233M | -$306M | -$178M | -$81M | -$57M | -$79M |
Cash flow
Fiscal years, from Fortress Biotech Inc Pref Series A's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$46M | -$81M | -$99M | -$95M | -$84M | -$117M | -$179M | -$128M | -$80M | -$66M |
| Capital spending | $6M | $648,000 | $7M | $2M | $2M | $5M | $3M | $63,000 | $0 | — |
| Free cash flow | -$52M | -$82M | -$106M | -$97M | -$86M | -$121M | -$182M | -$128M | -$80M | — |
| Stock-based compensation | $12M | $13M | $15M | $13M | $13M | $19M | $23M | $17M | $33M | $29M |
| Dividends paid | — | — | — | $0 | $237,000 | $749,000 | $749,000 | $736,000 | $694,000 | $664,000 |
| Share buybacks (net) | — | — | — | $0 | -$70,000 | — | — | — | — | — |
| Net borrowing | — | — | — | — | — | -$10M | $47M | -$50M | $0 | — |
| Free cash flow margin | -316.6% | -475.2% | -453.2% | -278.6% | -192.2% | -191.8% | -256.5% | -215.0% | -145.4% | — |
| Dividends per share | — | — | — | — | $0.05 | $0.14 | $0.13 | $0.09 | $0.03 | $0.02 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for FBIOP.
Open FBIOP in InvestinglyQuestions
What was Fortress Biotech Inc Pref Series A's revenue in 2025?
$61M in fiscal 2025, from its 10-K filing.
From Fortress Biotech Inc Pref Series A's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.